Clinical trials
Amyloidosis clinical trials
Below are recruiting amyloidosis clinical trials, each written for real people, not researchers. We’re tracking 150 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05577819Recruiting
Screening for ATTR heart amyloid in older HFpEF patients
This study looks at how often a specific heart condition (ATTR amyloid) occurs in people age 65+ who have HFpEF. It also tries to predict who might have it, using a special heart scan, and may help your care team identify it earlier.
Boston, MassachusettsAges 65 years+ - NCT05444920Recruiting
Web network for people with amyloidosis in Italy
This trial builds an Italian online network to learn from people who may have amyloidosis (an abnormal protein condition). It collects information from participating centers and could help doctors better understand different types of amyloidosis.
Legnano, MIAges 18–99 - NCT05139797Recruiting
AI-guided heart ultrasound screening for suspected amyloidosis
This study tests whether an artificial-intelligence system can help decide who should get a special heart workup for a rare disease called cardiac amyloidosis. If you have signs that make doctors suspect this, the AI-guided ultrasound screening may help find it sooner.
Los Angeles, CaliforniaAges 18 years+ - NCT04839003Recruiting
Registry for AL amyloidosis patients to track outcomes
This study collects information from adults with systemic AL amyloidosis to better understand the disease and outcomes. Because it includes pre-treatment records and follows people over time, it may help future patients by improving knowledge of how AL amyloidosis progresses and responds to care.
PaviaAges 18–99 - NCT04636684Recruiting
Study ATTR deposits in the aortic valve
This study looks at how common ATTR-related protein deposits are in the heart valve of people with age-related (degenerative) aortic stenosis. It may help doctors understand how important these deposits are and could guide future treatment decisions.
ToulouseAges 18–99 - NCT04667494RecruitingPhase 4
Ultrasound treatment for heart amyloidosis
This trial studies whether ultrasound therapy can help people with amyloidosis that affects the heart. It’s aimed at improving heart-related outcomes in AL or transthyretin (ATTR) cardiac amyloidosis.
Boston, MassachusettsAges 18–90 - NCT04210791Enrolling by invitation
Stem cell transplant using your own cells for AL amyloidosis
This trial tests whether an autologous stem cell transplant (using your own stem cells) can help people with newly diagnosed AL amyloidosis. It may be offered to help your body reset abnormal disease-producing cells, based on your health and test results.
Nanjing, JiangsuAges 18–75 - NCT01408225Recruiting
Myeloma and amyloidosis patient data and sample registry
This study collects health information and, if needed, samples from people diagnosed with certain blood disorders related to plasma cells. Sharing your information may help researchers better understand these diseases and improve future care.
Columbus, OhioAges 18 years+ - NCT04924998Recruiting
Study for AL-CM treatment in adults at one hospital
This study is looking at a treatment approach for people diagnosed with AL-CM at a specific hospital. It may help researchers understand whether the treatment is safe and effective for patients like you.
Hangzhou, ZhejiangAges 18–80 - NCT04935021RecruitingPhase 4
Study of ATTR cardiac amyloidosis in patients and gene carriers
This study looks at ATTR cardiac amyloidosis (a condition caused by an inherited protein change) in people who have the disease or carry the gene. It may help researchers learn how ATTR affects the heart and how care can be improved.
Hangzhou, ZhejiangAges 18–80 - NCT04265040Recruiting
Heart muscle disease registry for non-ischemic conditions
This trial is a registry, meaning it collects health information to help doctors study heart muscle diseases and plan future cardiovascular studies. You may be able to join if you have a non-ischemic cardiomyopathy such as dilated cardiomyopathy, certain forms of thick heart muscle, non-compaction, or arrhythmogenic right-sided disease.
Heidelberg, Baden-WurttembergAges 18–80 - NCT07850284Recruiting
Text message symptom check-ins for blood cancer patients
This study uses text messages to check how you're feeling during cancer treatment. It may help your care team respond sooner to symptoms and improve your quality of life.
Rochester, MinnesotaAges 18 years+ - NCT07829705RecruitingPhase 2
Amyloid PET scan to measure treatment response in AL cardiac amyloidosis
This study uses an amyloid PET/CT scan to see how well first-line treatment is working in people with AL cardiac amyloidosis, a condition where abnormal proteins build up in the heart. The scan may help doctors better understand and monitor the disease.
BeijingAges 18 years+ - NCT05593679Recruiting
Registry study for heart PYP scans in possible ATTR amyloidosis
This study collects information from adults who have been diagnosed with, or are being checked for, ATTR amyloidosis (a condition where abnormal protein builds up in the body) using a heart PYP scan. Your participation may help doctors better understand how these scans relate to diagnosis and follow-up over time.
New Taipei CityAges 20 years+ - NCT07560306RecruitingPhase 3
New Heart Scan to Detect Blood Clots in Amyloid Heart Disease
This study tests a new type of imaging scan ([64Cu]FBP8 PET) to detect blood clots that may form in the heart's left atrial appendage (a small pouch in the heart) in patients with amyloid cardiomyopathy (a disease where abnormal protein builds up in heart muscle) who also have irregular heartbeat. The scan may help doctors catch clots earlier and prevent strokes.
Boston, MassachusettsAges 18 years+ - NCT07448623RecruitingPhase 1
Testing coramitug for ATTR amyloid heart disease
This study tests a new medication called coramitug to see if it can reduce abnormal protein deposits in the heart. You will have special PET/CT scans to measure how the drug affects these deposits.
GroningenAges 60 years+ - NCT06813443Recruiting
Studying cardiomyopathy to find who needs a heart transplant
This study is looking at people with cardiomyopathy to understand which patients are most in need of a heart transplant. By joining, you will help doctors learn more about critical cases and improve care for heart muscle disease.
Bologna, Emilia-Romagna/BolognaAges 12 years+ - NCT07398950Enrolling by invitation
AI screening for a heart condition called ATTR-CM
This study uses artificial intelligence (AI) to look at your heart tests (ECG and echo) and find people who might have a specific heart muscle disease called ATTR-CM. The goal is to catch it earlier so treatment can start sooner.
New Haven, ConnecticutAges 18 years+ - NCT07358078Recruiting
Long-term study of ATTR-CM patients on vutrisiran or other approved therapies
This study observes people with ATTR-CM (a heart condition caused by a protein called transthyretin) who are starting treatment with vutrisiran or another approved therapy. It aims to understand how the disease progresses and how treatments work in real life.
Tucson, ArizonaAges 18 years+ - NCT07359690Recruiting
Study of Heart Muscle Biopsies
This study collects samples of heart muscle tissue (biopsy) to better understand heart conditions. It is for people who already need this biopsy for their healthcare.
Essen, North Rhine-WestphaliaAges 18 years+ - NCT07336394Recruiting
Study on rare heart muscle diseases using advanced MRI
This study uses a special heart MRI to better diagnose and understand rare heart muscle diseases. It may help doctors predict risks and make more accurate treatment decisions.
BeijingAges Any age - NCT06866912Recruiting
Observational study of amyloidosis and TTR gene carriers
This study is observing people with amyloidosis or those who carry a specific gene mutation (transthyretin) to learn more about the condition. It does not test any new treatment, but may help researchers understand how the disease affects people.
BolognaAges 18–99 - NCT07306949RecruitingPhase 4
Acoramidis for transthyretin cardiac amyloidosis
This trial tests a new medicine called acoramidis for people with a heart condition caused by a protein called transthyretin. It includes people who are newly diagnosed or who are already taking another drug (tafamidis) and may benefit from switching. The goal is to see how well acoramidis works and how it affects heart-related measures.
Bunkyō CityAges 18–100 - NCT07308704Recruiting
Using AI to spot heart muscle disease on echocardiograms
This study at Mayo Clinic is testing an artificial intelligence (AI) tool that analyzes echocardiograms (ultrasound of the heart) to find early signs of four types of heart muscle disease. If the AI flags a high-risk pattern, doctors can learn whether acting on that alert helps catch the condition sooner.
Rochester, MinnesotaAges 18 years+
Hear when a new Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for amyloidosis?
- Yes. Clin2 currently lists 150 recruiting amyloidosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a amyloidosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a amyloidosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.